Beryl Drugs Intrinsic Value
Beryl Drugs (BERLDRG) median intrinsic value is ₹40.00 from 8 valuation models (range ₹6–₹53), vs current price ₹21.22 — +88.5% upside (Trading Below Calculated Value), margin of safety 47.0%. For current market price and key ratios, visit Beryl Drugs screener.
BERLDRG Valuation Methods Summary — DCF, Graham Number & P/E
Beryl Drugs intrinsic value across 8 models vs current price ₹21.22 — upside/downside and value range per method. Analyse Beryl Drugs shareholding analysis to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹18.48 | ₹14.78 - ₹22.18 | -12.9% | EPS: ₹0.84, Sector P/E: 22x |
| Book Value Method | asset | ₹40.00 | ₹36.00 - ₹44.00 | +88.5% | Book Value/Share: ₹20.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹42.44 | ₹38.20 - ₹46.68 | +100.0% | Revenue/Share: ₹38.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹40.00 | ₹36.00 - ₹44.00 | +88.5% | EBITDA: ₹2.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹53.05 | ₹42.44 - ₹63.66 | +150.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹6.37 | ₹5.73 - ₹7.01 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹12.98 | ₹11.68 - ₹14.28 | -38.8% | Revenue Growth: 6.1%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹19.44 | ₹17.50 - ₹21.38 | -8.4% | EPS: ₹0.84, BVPS: ₹20.00 |
BERLDRG Intrinsic Value vs Market Price — All Valuation Models
Beryl Drugs fair value range ₹6–₹53 vs current market price ₹21.22 across 8 valuation models. Read BERLDRG dividend track record for the complete payout history and dividend yield track record.
BERLDRG Intrinsic Value Analysis — Undervalued or Overvalued?
Beryl Drugs median intrinsic value ₹40.00, current price ₹21.22 — Trading Below Calculated Value by 88.5%, margin of safety 47.0%.
What is the intrinsic value of BERLDRG?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Beryl Drugs (BERLDRG) is ₹40.00 (median value). With the current market price of ₹21.22, this represents a +88.5% variance from our estimated fair value.
The valuation range spans from ₹6.37 to ₹53.05, indicating ₹6.37 - ₹53.05.
Is BERLDRG undervalued or overvalued?
Based on our multi-method analysis, Beryl Drugs (BERLDRG) appears to be trading below calculated value by approximately 88.5%.
BERLDRG Financial Health — Key Ratios vs Industry Benchmarks
Beryl Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 10.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.27x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
BERLDRG Cash Flow Quality — Operating & Free Cash Flow
Beryl Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |